Kiniksa Price To Sales Ratio from 2010 to 2024

KNSA Stock  USD 21.80  0.52  2.44%   
Kiniksa Pharmaceuticals' Price To Sales Ratio is decreasing over the years with slightly volatile fluctuation. Price To Sales Ratio is expected to dwindle to 4.32. Price To Sales Ratio is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing Kiniksa Pharmaceuticals' market cap by its total sales or revenue over a 12-month period. View All Fundamentals
 
Price To Sales Ratio  
First Reported
2010-12-31
Previous Quarter
4.54687547
Current Value
4.32
Quarterly Volatility
6.79558477
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Kiniksa Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kiniksa Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 1.6 M, Interest Income of 1.6 M or Depreciation And Amortization of 1.9 M, as well as many indicators such as Price To Sales Ratio of 4.32, Dividend Yield of 0.0 or PTB Ratio of 2.94. Kiniksa financial statements analysis is a perfect complement when working with Kiniksa Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Kiniksa Pharmaceuticals Correlation against competitors.
For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.

Latest Kiniksa Pharmaceuticals' Price To Sales Ratio Growth Pattern

Below is the plot of the Price To Sales Ratio of Kiniksa Pharmaceuticals over the last few years. Price to Sales Ratio is figured by comparing Kiniksa Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Kiniksa Pharmaceuticals sales, a figure that is much harder to manipulate than other Kiniksa Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Kiniksa Pharmaceuticals' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kiniksa Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 4.10 X10 Years Trend
Slightly volatile
   Price To Sales Ratio   
       Timeline  

Kiniksa Price To Sales Ratio Regression Statistics

Arithmetic Mean17.66
Geometric Mean15.41
Coefficient Of Variation38.48
Mean Deviation5.25
Median20.94
Standard Deviation6.80
Sample Variance46.18
Range16.621
R-Value(0.70)
Mean Square Error25.69
R-Squared0.48
Significance0
Slope(1.06)
Total Sum of Squares646.52

Kiniksa Price To Sales Ratio History

2024 4.32
2023 4.55
2022 4.72

About Kiniksa Pharmaceuticals Financial Statements

Kiniksa Pharmaceuticals stakeholders use historical fundamental indicators, such as Kiniksa Pharmaceuticals' Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although Kiniksa Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Kiniksa Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Kiniksa Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Kiniksa Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price To Sales Ratio 4.55  4.32 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Kiniksa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kiniksa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kiniksa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kiniksa Pharmaceuticals Stock:
Check out the analysis of Kiniksa Pharmaceuticals Correlation against competitors.
For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. If investors know Kiniksa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiniksa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
5.5
Earnings Share
(0.12)
Revenue Per Share
5.415
Quarterly Revenue Growth
0.674
Return On Assets
(0.03)
The market value of Kiniksa Pharmaceuticals is measured differently than its book value, which is the value of Kiniksa that is recorded on the company's balance sheet. Investors also form their own opinion of Kiniksa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiniksa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiniksa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiniksa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiniksa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiniksa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiniksa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.